Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00999791

Enrollment

Unknown

Registered

2009-10-22

Start date

2009-07-31

Completion date

Unknown

Last updated

2010-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Diabetic Macular Edema

Brief summary

Diffuse Macular Edema is the main cause of visual disorders in diabetic patients. Diclofenac is a cheap drug available in most of treatment centers.in animal studies the safe dosage is identified that can be used in diffuse diabetic macular edema for treatment. in this study, we are going to compare the effect of intra vitreal injection of Diclofenac and Bevacizumab in primary treatment of diffuse diabetic macular edema.

Detailed description

Interventions

DRUGBevacizumab

DRUGDiclofenac

Study design

Intervention model

PARALLEL

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Inclusion criteria

* patients with clinically significant macular edema and diffuse macular edema

Exclusion criteria

* any history of focal photocoagulation * any prior intra ocular injection * history of glaucoma with high pressure * history of ophthalmic surgery * high rish PDR * active PDR

Countries

Iran

Contacts

Primary ContactMasoud Soheilian, MD

labbafi@hotmail.com+982122585952

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026